HIV vaccine acceptability among high-risk drug users in Appalachia: a cross-sectional study

BMC Public Health

Jennifer R Havens¹  Claire E Sterk²  Daniel S Halgin³  Ralph J DiClemente²  April M Young² 

[1] Center on Drug and Alcohol Research, University of Kentucky, 333 Waller Avenue, Lexington, KY 40504, USA;Department of Behavioral Sciences and Health Education, Emory University, 1518 Clifton Road, Atlanta, GA 30322, USA;LINKS Center for Social Network Analysis, Gatton College of Business and Economics, University of Kentucky, 550 S Limestone St, Lexington, KY 40526, USA

关键词: Rural health;    Psychological theory;    Drug users;    Attitude;    HIV vaccines;    AIDS vaccines;    Vaccination;    HIV;   

Others  :  1130010
DOI  :  10.1186/1471-2458-14-537

 received in 2014-03-06, accepted in 2014-05-23,  发布年份 2014

【 摘 要 】

Background

A vaccine could substantially impact the HIV epidemic, but inadequate uptake is a serious concern. Unfortunately, people who use drugs, particularly those residing in rural communities, have been underrepresented in previous research on HIV vaccine acceptability. This study examined HIV vaccine acceptability among high-risk drug users in a rural community in the United States.

Methods

Interviewer-administered questionnaires included questions about risk behavior and attitudes toward HIV vaccination from 433 HIV-negative drug users (76% with history of injection) enrolled in a cohort study in Central Appalachia. HIV vaccine acceptability was measured on a 4-point Likert scale. Generalized linear mixed models were used to determine correlates to self-report of being “very likely” to receive a 90% effective HIV vaccine (i.e. “maximum vaccine acceptability”, or MVA). Adjusted odds ratios (AORs) and corresponding 95% confidence intervals (CIs) are reported.

Results

Most (91%) reported that they would accept a preventive HIV vaccine, but concerns about cost, dosing, transportation constraints, vaccine-induced seropositivity, and confidentiality were expressed. Cash incentives, oral-administration, and peer/partner encouragement were anticipated facilitators of uptake. In multivariate analysis, men were significantly less likely to report MVA (AOR: 0.33, CI: 0.21 – 0.52). MVA was more common among participants who believed that they were susceptible to HIV (AOR: 2.31, CI: 1.28 – 4.07), that an HIV vaccine would benefit them (AOR: 2.80, CI: 1.70 – 4.64), and who had positive experiential attitudes toward HIV vaccination (AOR: 1.85, CI: 1.08 – 3.17). MVA was also more common among participants who believed that others would encourage them to get vaccinated and anticipated that their behavior would be influenced by others' encouragement (AOR: 1.81, 95% 1.09 – 3.01).

Conclusions

To our knowledge, this study was among the first to explore and provide evidence for feasibility of HIV vaccination in a rural, high-risk population in the United States. This study provides preliminary evidence that gender-specific targeting in vaccine promotion may be necessary to promoting vaccine uptake in this setting, particularly among men. The data also underscore the importance of addressing perceived risks and benefits, social norms, and logistical constraints in efforts to achieve widespread vaccine coverage in this high-risk population.

【 授权许可】

   
2014 Young et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Girard M, Osmanov S, Assossou O, Kieny M: Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 2011, 29:6191-6218.
• [2]Newman P, Lee S-J, Rudy E, Diamant A, Duan N, Nakazano T, Cunningham W: Endorsement of Compulsory HIV Vaccination Policy Among Populations at High Risk of HIV Exposure (LA VOICES). Prev Sci 2014, 15(3):428-435.
• [3]Newman P, Logie C: HIV vaccine acceptability: a systematic review and meta-analysis. AIDS 2010, 24(11):1749-1756.
• [4]Crosby R, Holtgrave DR, Bryant L, Frew PM: Correlates of negative intent to receive an AIDS vaccine: an exploratory study. Int J STD AIDS 2004, 15(8):552-557.
• [5]Newman P, Duan N, Lee S-J, Rudy ET, Seiden DS, Kakinami L, Cunningham WE: HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine 2006, 24(12):2094-2101.
• [6]Newman P, Lee SJ, Duan N, Rudy E, Nakazono TK, Boscardin J, Kakinami L, Shoptaw S, Diamant A, Cunningham WE: Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). Health Serv Res 2009, 44(6):2167-2179.
• [7]Newman P, Duan N, Rudy ET, Roberts KJ, Swendeman D: Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr 2004, 37(3):1393-1403.
• [8]Newman P, Seiden DS, Roberts KJ, Kakinami L, Duan N: A small dose of HIV? HIV vaccine mental models and risk communication. Health Educ Behav 2009, 36(2):321-333.
• [9]Rudy ET, Newman P, Duan N, Kelly EM, Roberts KJ, Seiden DS: HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev 2005, 17(3):253-267.
• [10]Roberts KJ, Newman P, Duan N, Rudy ET: HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion. J Natl Med Assoc 2005, 97(12):1662-1671.
• [11]Newman P, Duan N, Kakinami L, Roberts K: What can HIV vaccine trials teach us about future HIV vaccine dissemination? Vaccine 2008, 26(20):2528-2536.
• [12]Centers for Disease Control and Prevention: Cases of HIV infection and AIDS in urban and rural areas of the United States, 2006. HIV/AIDS surveillance supplemental report 2008, 13(2):1-25.
• [13]HIV surveillance in urban and nonurban areas (through 2011) http://www.cdc.gov/hiv/pdf/statistics_surveillance_urban-nonurban.pdf webcite
• [14]Economic overview of Appalachia 2011 http://www.arc.gov/images/appregion/Sept2011/EconomicOverviewSept2011.pdf webcite
• [15]Halverson J: An analysis of disparities in health status and access to health care in the Appalachian Region. Office of Social Environment and Health Research (OSEAHR)/Prevention Research Center 2004.
• [16]An analysis of mental health and substance abuse disparities and access to treatment services in the Appalachian region http://www.arc.gov/assets/research_reports/AnalysisofMentalHealthandSubstanceAbuseDisparities.pdf webcite
• [17]Cicero TJ, Inciardi JA, Munoz A: Trends in abuse of OxyContin® and other analgesics in the United States: 2002–2004. J Pain 2005, 6(10):11.
• [18]Havens J, Oser CB, Leukefeld C, Webster JM, Martin SS, O'Connell DJ, Surratt HL, Inciardi JA: Differences in prevalence of presctiption opiate misuse among rural and urban probationers. Am J Drug Alcohol Abuse 2007, 33(2):309-317.
• [19]Kentucky Cabinet for Health and Human Services: An integrated epidemiologic profile for HIV/AIDS prevention and care planning for Kentucky - 2010. In Department for Public Health, HIV/AIDS Branch Edited by Frankfort KY. 2012.
• [20]Havens J, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA: Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health 2013, 103(1):e44-e52.
• [21]Young A, Havens J: Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. Addiction 2012, 107(3):587-596.
• [22]Crosby R, Oser CB, Leukefeld CG, Havens J, Young A: Prevalence of HIV and risky sexual behaviors among rural drug users: does age matter? Ann Epidemiol 2012, 22(11):778-782.
• [23]Young A, Jonas A, Mullins U, Halgin D, Havens J: Network structure and the risk for HIV transmission among rural drug users. AIDS Behav 2013, 17(7):2341-2351.
• [24]Basta T: HIV-related stigma and knowledge among individuals living in rural Appalachian Ohio. In Paper presented at: AIDS 2010 - XVIII International AIDS Conference; July 20, 2010. Vienna, Austria;
• [25]Young AM, Rudolph AE, Quillen D, Havens JR: Spatial, temporal and relational patterns in respondent-driven sampling: evidence from a social network study of rural drug users. J Epidemiol Community Health[Published Online First: 1 April, 2014]. doi:10.1136/jech-2014-203935
• [26]Poole G: Using psychological principles to narrow the intention-behavior gap and increase participation in HIV vaccine trials. Curr HIV Res 2012, 10(6):552-556.
• [27]Suraratdecha C, Ainsworth M, Tangcharoensathien V, Whittington D: The private demand for an AIDS vaccine in Thailand. Health Policy 2005, 71(3):271-287.
• [28]Newman P, Roungprakhon S, Tepjan S, Yim S: Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 2010, 28:958-964.
• [29]Montaño DE, Kaspryzyk D: Theory of reasoned action, theory of planned behavior, and the integrated behavioral model. In Health Behavior and Health Education: Theory, Research, and Practice. 4th edition. Edited by Glanz K, Rimer BK, Viswanath K. San Francisco: John Wiley & Sons; 2008.
• [30]Fishbein M: A reasoned action approach to health promotion. Med Decis Making 2008, 28(6):834-844.
• [31]Fishbein M: A reasoned action approach: some issues, questions, and clarifications. In Prediction and change of health behavior: applying the reasoned action approach. Edited by Azjen I, Albarracin D, Hornick R. Hillsdale, NJ: Erlbaum; 2007.
• [32]Gagnon M, Godin G: Young adults and HIV vaccine: determinants of the intention of getting immunized. Can J Public Health 2000, 91(6):432-434.
• [33]Rosenstock I: What research in motivation suggests for public health. Am J Public Health 1960, 50:295-302.
• [34]Fishbein M: An integrative model for behavioral prediction and its application to health promotion. In Emerging theories in health promotion practice and research. Edited by DiClemente RJ, Crosby RA, Kegler MC. San Francisco: John Wiley & Sons; 2009.
• [35]Cialdini RB, Reno RR, Kallgren CA: A focus theory of normative conduct: Recycling the concept of norms to reduce littering in public places. J Pers Soc Psychol 1990, 58(6):1015-1026.
• [36]Bandura A: Social cognitive theory of self-regulation. Organ Behav Hum Decis Process 1991, 50(2):248-287.
• [37]Ajzen I: The theory of planned behaviour: Reactions and reflections. Psychol Health 2011, 26(9):1113-1127.
• [38]SAS Institute: The GLIMMIX Procedure. In SAS/STAT 93 User's Guide. Cary, NC: SAS Institute; 2011.
• [39]Wolfinger R: Laplace's approximation for nonlinear mixed models. Biometrika 1993, 80(4):791-795.
• [40]Heckathorn D: Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl 1997, 44(2):174-199.
• [41]Heckathorn D: Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Soc Probl 2002, 49(1):11-34.
• [42]Volz E, Wejnert C, Cameron C, Spiller M, Barash V, Degani I, Heckathorn D: Respondent-driven Sampling Analysis Tool (RDSAT) Version 7.1. Ithaca, NY: Cornell University; 2012.
• [43]Hennessy M, Bleakley A, Fishbein M, Brown L, DiClemente R, Romer D, Valois R, Vanable PA, Carey MP, Salazar L: Differentiating between precursor and control variables when analyzing reasoned action theories. AIDS Behav 2010, 14(1):225-236.
• [44]The Appalachian Region: A data overview from the 2007–2011 American Community Survey http://www.arc.gov/assets/research_reports/PRBDataOverviewReport2007-2011.pdf webcite
• [45]Webb PM, Zimet GD, Mays R, Fortenberry JD: HIV immunization: Acceptability and anticipated effects on sexual behavior among adolescents. J Adolesc Health 1999, 25(5):320-322.
• [46]Lally MA, Gaitanis M, Vallabhaneni S, Reinert S, Mayer K, Zimet G, Rich J: Willingness to receive an HIV vaccine among incarcerated persons. Prev Med 2006, 43(5):402-405.
• [47]Seal KH, Kral AH, Lorvick J, McNees A, Gee Lm Edlin BR: A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 2003, 71(2):127-131.
• [48]Bishai D, Pariyo G, Ainsworth M, Hill K: Determinants of personal demand for an AIDS vaccine in Uganda: contingent valuation survey. Bull WHO 2004, 82(9):652-660.
• [49]Kakinami L, Newman P, Lee SJ, Duan N: Differences in HIV vaccine acceptability between genders. AIDS Care 2008, 20(5):542-546.
• [50]Newman P, Duan N, Rudy ET, Anton PA: Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come? Aids Patient Care STDS 2004, 18(12):691-701.
• [51]Liau A, Zimet GD, Fortenberry JD: Attitudes about human immunodeficiency virus immunization: the influence of health beliefs and vaccine characteristics. Sex Transm Dis 1998, 25(2):76-81.
• [52]Sayles JN, Macphail CL, Newman P, Cunningham WE: Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav 2010, 37(2):193-210.
• [53]Barrington C, Moreno L, Kerrigan D: Local understanding of an HIV vaccine and its relationship with HIV-related stigma in the Dominican Republic. AIDS Care 2007, 19(7):871-877.
• [54]Newman P, Woodford MR, Logie C: HIV vaccine acceptability and culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada. Glob Public Health 2012, 7(1):87-100.
• [55]Newman P, Roungprakhon S, Tepjan S, Yim S, Walisser R: A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. Glob Public Health 2012, 7(9):1009-1024.
• [56]Mills E, Cooper C, Guyatt G, Gilchrist A, Rachlis B, Sulway C, Wilson K: Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 2004, 18(17):2235-2242.
• [57]Young AM, DiClemente RJ, Halgin D, Sterk C, Havens JR: Drug users' willingness to encourage social, sexual, and drug network members to receive an HIV vaccine: A social network analysis. AIDS BehavIn press
• [58]Lee SJ, Brooks RA, Newman P, Seiden D, Sangthong R, Duan N: HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach. AIDS Care 2008, 20(10):1161-1168.
• [59]Lee S, Newman P, Comulada W, Cunningham W, Duan N: Use of conjoint analysis to assess HIV vaccine acceptability: feasibility of an innovation in the assessment of consumer health-care preferences. Int J STD AIDS 2012, 23(4):235-241.
• [60]Cameron MP, Newman PA, Roungprakhon S, Scarpa R: The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine 2013, 31(36):3712-3717.